The Ductal Carcinoma In Situ drugs in development market research report provides comprehensive information on the therapeutics under development for Ductal Carcinoma In Situ, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Ductal Carcinoma In Situ. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Ductal Carcinoma In Situ and features dormant and discontinued products.
GlobalData tracks six drugs in development for Ductal Carcinoma In Situ by five companies/universities/institutes. The top development phase for Ductal Carcinoma In Situ is phase i with three drugs in that stage. The Ductal Carcinoma In Situ pipeline has five drugs in development by companies and one by universities/ institutes. Some of the companies in the Ductal Carcinoma In Situ pipeline products market are: Marker Therapeutics, F. Hoffmann-La Roche and Atossa Therapeutics.
The key targets in the Ductal Carcinoma In Situ pipeline products market include Receptor Tyrosine Protein Kinase ERBB 2, Protein Kinase C Beta Type, and Mucin 1.
The key mechanisms of action in the Ductal Carcinoma In Situ pipeline product include Estrogen Receptor Antagonist with one drug in Phase II. The Ductal Carcinoma In Situ pipeline products include six routes of administration with the top ROA being Intradermal and three key molecule types in the Ductal Carcinoma In Situ pipeline products market including Subunit Vaccine, and Monoclonal Antibody.
Ductal Carcinoma In Situ overview
Ductal carcinoma in situ (DCIS), also referred to as intraductal carcinoma, is a non-invasive breast cancer characterized by a proliferation of abnormal epithelial cells confined within the basement membrane. Disruption of the basement membrane layer would change the diagnosis from DCIS to invasive breast cancer. DCIS is considered to be a precursor for invasive breast cancer.
For a complete picture of Ductal Carcinoma In Situ’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
